$RCKT News

Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15

Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease

Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation?

Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?

Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?

Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M

Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says

Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate

Rocket to sell PRV for $180m to advance gene therapy pipeline

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9

Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI

Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy

Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited

Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids

Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI